scholarly journals Locus coeruleus response to single-prolonged stress and early intervention with intranasal neuropeptide Y

2015 ◽  
Vol 135 (5) ◽  
pp. 975-986 ◽  
Author(s):  
Esther L. Sabban ◽  
Marcela Laukova ◽  
Lishay G. Alaluf ◽  
Emelie Olsson ◽  
Lidia I. Serova
Keyword(s):  
Early Intervention ◽  
Neuropeptide Y ◽  
Locus Coeruleus ◽  
Single Prolonged Stress ◽  
Prolonged Stress

scholarly journals Altered locus coeruleus-norepinephrine function following single prolonged stress

2012 ◽  
Vol 37 (6) ◽  
pp. 901-909 ◽  
Author(s):  
Sophie A. George ◽  
Dayan Knox ◽  
Andre L. Curtis ◽  
J. Wayne Aldridge ◽  
Rita J. Valentino ◽  
...  
Keyword(s):  
Locus Coeruleus ◽  
Single Prolonged Stress ◽  
Prolonged Stress

Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model

2014 ◽  
Vol 24 (1) ◽  
pp. 142-147 ◽  
Author(s):  
L.I. Serova ◽  
M. Laukova ◽  
L.G. Alaluf ◽  
L. Pucillo ◽  
E.L. Sabban
Keyword(s):  
Neuropeptide Y ◽  
Single Prolonged Stress ◽  
Prolonged Stress

scholarly journals Early Intervention With Intranasal NPY Prevents Single Prolonged Stress-Triggered Impairments in Hypothalamus and Ventral Hippocampus in Male Rats

Endocrinology ◽  
2014 ◽  
Vol 155 (10) ◽  
pp. 3920-3933 ◽  
Author(s):  
Marcela Laukova ◽  
Lishay G. Alaluf ◽  
Lidia I. Serova ◽  
Victoria Arango ◽  
Esther L. Sabban
Keyword(s):  
Early Intervention ◽  
Hpa Axis ◽  
Traumatic Stress ◽  
Feedback Inhibition ◽  
Neuropsychiatric Symptoms ◽  
Ventral Hippocampus ◽  
Male Rats ◽  
Nuclear Fraction ◽  
Single Prolonged Stress ◽  
Prolonged Stress

Abstract Intranasal administration of neuropeptide Y (NPY) is a promising treatment strategy to reduce traumatic stress-induced neuropsychiatric symptoms of posttraumatic stress disorder (PTSD). We evaluated the potential of intranasal NPY to prevent dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, a core neuroendocrine feature of PTSD. Rats were exposed to single prolonged stress (SPS), a PTSD animal model, and infused intranasally with vehicle or NPY immediately after SPS stressors. After 7 days undisturbed, hypothalamus and hippocampus, 2 structures regulating the HPA axis activity, were examined for changes in glucocorticoid receptor (GR) and CRH expression. Plasma ACTH and corticosterone, and hypothalamic CRH mRNA, were significantly higher in the vehicle but not NPY-treated group, compared with unstressed controls. Although total GR levels were not altered in hypothalamus, a significant decrease of GR phosphorylated on Ser232 and increased FK506-binding protein 5 mRNA were observed with the vehicle but not in animals infused with intranasal NPY. In contrast, in the ventral hippocampus, only vehicle-treated animals demonstrated elevated GR protein expression and increased GR phosphorylation on Ser232, specifically in the nuclear fraction. Additionally, SPS-induced increase of CRH mRNA in the ventral hippocampus was accompanied by apparent decrease of CRH peptide particularly in the CA3 subfield, both prevented by NPY. The results show that early intervention with intranasal NPY can prevent traumatic stress-triggered dysregulation of the HPA axis likely by restoring HPA axis proper negative feedback inhibition via GR. Thus, intranasal NPY has a potential as a noninvasive therapy to prevent negative effects of traumatic stress.

scholarly journals Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress

2015 ◽  
Vol 295 ◽  
pp. 9-16 ◽  
Author(s):  
Esther L. Sabban ◽  
Lidia I. Serova ◽  
Lishay G. Alaluf ◽  
Marcela Laukova ◽  
Chandana Peddu
Keyword(s):  
Neuropeptide Y ◽  
Single Prolonged Stress ◽  
Prolonged Stress

scholarly journals Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females

2021 ◽  
Vol 15 ◽  
Author(s):  
Roxanna J. Nahvi ◽  
Arax Tanelian ◽  
Chiso Nwokafor ◽  
Callie M. Hollander ◽  
Lauren Peacock ◽  
...  
Keyword(s):  
Neuropeptide Y ◽  
Therapeutic Potential ◽  
Forced Swim Test ◽  
Combined Treatment ◽  
Female Rats ◽  
High Dose ◽  
Sprague Dawley ◽  
Dose Requirement ◽  
Single Prolonged Stress ◽  
Prolonged Stress

The susceptibility to stress-elicited disorders is markedly influenced by sex. Women are twice as likely as men to develop posttraumatic stress disorder (PTSD), depression, anxiety disorders, and social impairments following exposure to traumatic stress. However, most of the studies in animal models examining putative therapeutics for stress-triggered impairments, including single prolonged stress (SPS), were performed predominantly with males. Previous studies in males demonstrated that intranasal neuropeptide Y (NPY) can provide therapeutic relief of many SPS-triggered behaviors, but is ineffective in females at the same dose. Thus, females may need a higher dose of exogenous NPY to attain a therapeutically significant concentration since the overwhelming majority of studies found that NPY levels in females in many brain regions are lower than in male rodents. Here, we examined SPS as an appropriate model to elicit many PTSD-associated symptoms in females and whether intranasal NPY at higher doses than with males is able to alter the development of SPS-triggered behavioral impairments. Sprague-Dawley female rats were exposed to SPS only, or in a separate cohort after SPS stressors were immediately infused intranasally with one of several doses of NPY, starting with 600 μg/rat—four times the dose effective in males. In the third cohort of animals, females were infused intranasally with either 600 μg NPY, omarigliptin [a dipeptidyl peptidase IV (DPP4) inhibitor], or both right after the SPS stressors. After 19 days they were tested on several behavioral tests. SPS elicited significant depressive/despair like behavior on the forced swim test (FST), anxiety behavior on the elevated plus maze (EPM), as well as impaired social interaction. On the FST, there was a dose-response effect of intranasal NPY, with 1,200 μg, but not 600 μg, preventing the development of the SPS-elicited depressive-like behavior. The omarigliptin and 600 μg NPY combined treatment, but neither alone, was also sufficient at preventing depressive-like behavior on the FST. The results demonstrate that: (1) SPS elicits several behavioral manifestations of PTSD in females; (2) early intervention with a high dose of intranasal NPY has therapeutic potential also for females; and (3) NPY cleavage by DPP4 may play a role in the higher dose requirement for females.

Sign in / Sign up

Export Citation Format

Share Document